    Brett Haumann | Theravance , Inc. | ZoomInfo.com










 





TBPH Brett K. Haumann Insider Trades for Theravance Biopharma Inc.


































Bulletin






Investor Alert





















Expand
Keep Open
Close






Expand
Keep Open
Close






Expand
Keep Open
Close






Expand
Keep Open
Close






Expand
Keep Open
Close































Theravance Biopharma Inc.

                  NASDAQ: TBPH
          



GO



Set Alerts
Find a Broker




Join TD Ameritrade




Market Index


 

Overview
      
Profile
      
News
      
Charts
      
Financials
      
Historical Quotes
      
Analyst Estimates
      
Options
      
SEC Filings
      
Insiders
      


/marketstate/country/us

Theravance Biopharma Inc.



After Hours
 --Quotes are delayed by 20 min
Jul 28, 2017, 4:30 p.m.


TBPH

/quotes/zigman/33700546/composite


$
32.81




Change

0.00
0.00%

Volume
Volume 3,609
Quotes are delayed by 20 min








/quotes/zigman/33700546/composite
Today's close

$
			33.48
		


$
				32.81
			
Change

-0.67
-2.00%





Day low
Day high
$32.60
$34.39










52 week low
52 week high

            $23.80
        

            $43.44
        


















Insider Activity


Individual




Brett K. Haumann



Dr. Brett K. Haumann is Chief Medical Officer & SVP-Clinical Development at Theravance Biopharma, Inc. Dr. Haumann was previously employed as Chief Medical Officer by Circassia Ltd. He received his MBA from The Open University and a doctorate degree from the University of the Witwatersrand.



Transactions


Date
Shares
Transaction
Value





05/20/2017
7,065


 
Derivative/Non-derivative trans. at $36.83 per share.


260,204


03/07/2017
424


 
Disposition at $30.8 per share.


13,060


03/06/2017
13,576


 
Disposition at $31.52 per share.


427,916


02/20/2017
14,434


 
Derivative/Non-derivative trans. at $33.78 per share.


487,581


02/06/2017
9,000


 
Award at $0 per share.


0


11/20/2016
5,388


 
Derivative/Non-derivative trans. at $31.96 per share.


172,201


08/25/2016
4,491


 
Disposition at $27.99 per share.


125,704


08/20/2016
4,607


 
Derivative/Non-derivative trans. at $27.89 per share.


128,490


08/19/2016
9,509


 
Disposition at $27.97 per share.


265,967


05/20/2016
4,608


 
Derivative/Non-derivative trans. at $20.55 per share.


94,695


03/15/2016
90,000


 
Award at $0 per share.


0


02/20/2016
18,425


 
Derivative/Non-derivative trans. at $15.65 per share.


288,352


11/20/2015
781


 
Derivative/Non-derivative trans. at $17.17 per share.


13,410


02/05/2015
135,000


 
Award at $0 per share.


0





        Copyright 2017 FactSet Research Systems Inc. All rights reserved. Source FactSet Fundamentals.
    











            Officers and Executives
        





Mr. Rick E. Winningham 
Chairman & Chief Executive Officer




Ms. Renee D. Gala 
Chief Financial Officer, Treasurer & SVP




Dr. Sharath S. Hegde 
Senior Vice President-Research




Dr. Brett K. Haumann 
Chief Medical Officer & SVP-Clinical Development




Mr. Frank C. Pasqualone 
Chief Commercial Operations Officer & Senior VP




Dr. Philip  Worboys 
Senior Vice President-Translational Science




Dr. Junning  Lee 
Senior Vice President-Technical Operations




Mr. Alexander  Dobbin 
Head-Investor Relations




Mr. Dennis O. Driver 
Chief Human Resources Officer & Vice President




Mr. Bradford J. Shafer 
Secretary & Executive VP-General Counsel




Mr. Donal M. O'Connor 
Independent Director




Dr. Susan M. Molineaux 
Independent Director




Mr. Dean Jonathan Mitchell 
Independent Director




Mr. Eran  Broshy 
Independent Director




Mr. William D. Young 
Lead Independent Director




Dr. George M. Whitesides 
Independent Director




Dr. Peter S. Ringrose 
Independent Director




Dr. Burton Gordon Malkiel 
Independent Director




Mr. Robert V. Gunderson 
Independent Director




Ms. Henrietta Holsman Fore 
Independent Non-Executive Director









Trending Tickers


/quotes/zigman/17636479/composite VUZI+15.60%


/quotes/zigman/237947/composite JCP-5.83%


/quotes/zigman/59392505/composite NUGT-2.93%


/quotes/zigman/59386294/composite JNUG-5.94%


/quotes/zigman/65801738/composite TLT+1.11%


X




Powered by














Log In




9:36 PM EDT
July 28, 2017


/marketstate/country/us
New York

	Closed


/marketstate/country/uk
London

	Closed


/marketstate/country/jp
Tokyo

	Closed





/marketstate/country/us
 


/marketstate/country/uk
 


/marketstate/country/jp
 











View All



Latest News

/news/latest
9:16pWall Street isn’t ready for a 1,100-point tumble in the Dow industrials
7:39pBarron's Buzz: Robo 2.0, Facebook and Twitter, Trading On News
7:29pA Wild Week in Washington 
6:32pThe dark side of cruises
6:32pThe highest paid athletes in the world, in one chart
6:31pO.J. Simpson made over $400,000 while in prison and won’t have to give any of it to the Goldman family
6:31p Trump to Police: 'Don't Be Too Nice'
6:31pHere are 10 co-workers you should avoid like the plague — especially in meetings
6:29pTop 10 most annoying people you may want to unfriend on Facebook 
6:29pThis is one person you should never unfriend on Facebook...
6:29p3 horrible ways typos could alter the course of your life
6:27pPaint your bathroom this color and boost your home’s selling price by $5,400
6:27pAmericans’ new badge of honor: ‘I was blocked by a celebrity!’
6:27p5 weird things I found out about America in my first 24 hours 
6:14pBeyond Tesla: 7 stocks driving the autonomous car revolution
6:14pThese 7 highly taxed companies need Congress to finally act on tax reform
6:11pWatch out: ‘Kids’ are making the most money in this stock market 
6:10p7 real ways for millennials to save money (not by brownbagging and skipping Starbucks)
6:09p‘Game of Thrones’: This computer model predicts who will be killed off — or survive
6:09pThis basic balanced index fund is beating the hedge fund averages
Loading more headlines...




dow

/quotes/zigman/627449/realtime
21,830.31

+33.76
+0.15%





nasdaq

/quotes/zigman/12633936/realtime
6,374.68

-7.51
-0.12%





s&p 500

/quotes/zigman/3870025/realtime
2,472.10

-3.32
-0.13%













Kiosk


1352872800000
1352872800000


The RetireMentors






				Retirement advice from our industry experts
				Our team of financial professionals can help you plan and save 
					for retirement, then 
				live well in it.



/conga/kiosk/retirementors.html
361307




1320411600000
1320616500000


Alerts



/conga/kiosk/alerts.html
310238




1333717800000
1333964100000


Virtual Stock Exchange





Our free stock-market game
				• Trade your virtual portfolio in real time
				• Talk strategies in group discussions
				• Find or create a game that suits you
				• Use our learning center to improve 



/conga/kiosk/games.html
310284




1245657600000
1277280000000


Location Scouts




Housing-market insights from our realty pros
																																																							Plus the latest data from Realtor.com on 21 home markets across the U.S.
• See our complete Real Estate site


/conga/kiosk/real_estate.html
357012




1404799200000
1404799200000


Lazy Portfolios





				Set it and forget it
				Check out the returns on our 8 Lazy Portfolios that are made up 
				of low-cost 
				buy-and-hold index funds.

				• How to create your own Lazy Portfolio


/conga/kiosk/lazy_portfolio.html
313134














MarketWatch.com




Site Index
Topics
Help
Feedback
Newsroom Roster

                    Media Archive
Premium Products
Mobile


Company Info
Code of Conduct
Corrections
Advertising Media Kit
Advertise Locally
Reprints & Licensing
Broker Center

                    Your Ad Choices


Follow MarketWatch


































RSS
Podcasts






WSJ.com
Barron's Online
BigCharts
Virtual Stock Exchange


Financial News London
WSJ.com Small Business
realtor.com
Mansion Global












		Copyright © 2017 MarketWatch, Inc.  All rights reserved.
		By using this site, you agree to the Terms of Service,
        Privacy Policy and Cookie Policy.
	



            Intraday Data provided by SIX Financial Information and subject to terms of use. Historical and current end-of-day data provided by SIX Financial Information. All quotes are in local exchange time. Real-time last sale data for U.S. stock quotes reflect trades reported through Nasdaq only. Intraday data delayed at least 15 minutes or per exchange requirements.
        






MarketWatch Top Stories
Link to MarketWatch's Slice.

15
























































Brett Haumann, Theravance Biopharma Inc: Profile & Biography - Bloomberg


































































  

























Feedback





Brett Haumann

Senior VP:Clinical Dev/Chief Medical Ofcr,
Theravance Biopharma Inc






Career History




Senior VP:Clinical Dev/Chief Medical Ofcr
Theravance Biopharma Inc, 12/2014-PRESENT


VP:Clinical Dev & Ops
Theravance Biopharma Inc, 3/2014-12/2014


Executive Director
Circassia Holdings Ltd, 9/2012-7/2013


VP:Medicines Development Leader
Glaxosmithkline PLC, UNKNOWN-9/2012


Chief Medical Officer
Circassia Ltd, 9/2012-UNKNOWN


Various Positions
Glaxosmithkline PLC, FORMER


Show More









Website:
www.theravance.com






Corporate Information
Address:

PO Box 309
Ugland House, South Church Str
George Town, Grand Cayman, KY1-1104
Cayman Islands


Phone:
1-650-808-6000


Fax:
-


Web url:
www.theravance.com











From The Web












Personal Information



Education



University of The Witwatersrand
MD


Open University
MBA








Memberships



Board Memberships




Circassia Holdings Ltd


Board Member, 9/2012-7/2013









Sponsored Financial Commentaries







More From The Web


















Home


News


Top Headlines
Most Popular
Exclusive
Law
Entrepreneurs
Leaders
Economy
Environment
Science
Sports
Markets Magazine
Pursuits Magazine
Bloomberg Visual Data
Bloomberg Best (and Worst)
For comments or complaints about news coverage click here


Regions
U.S.
China
Europe
Asia
U.K. & Ireland
Australia & New Zealand
Canada
India & Pakistan
Japan
Africa
Eastern Europe
Latin America
Middle East
Markets
Commodities
Currencies
Bonds
Stocks
Energy Markets
Municipal Bonds
Emerging Markets
Funds
Islamic Finance
Industries
Energy
Technology
Real Estate
Finance
Health Care
Transportation
Insurance
Retail
Media
Manufacturing




Quick


Market Data


Stocks
Stock Futures
World Indexes
Americas
Europe, Middle East, & Africa
Asia-Pacific
Gainers & Losers
Earnings Calendar
Industry Leaders
Currencies
Americas
Europe, Middle East, & Africa
Asia-Pacific
Foreign Exchange Cross Rates
FX Fixings
Currency Converter
Forex Trading Videos
Commodities
Energy Prices
Metals Prices
Agricultural Prices


Rates & Bonds
US Treasuries
UK Gilts
Germany Bunds
Japan Bonds
Australia Bonds
Bloomberg Bond Indexes
Corporate Bonds
Consumer Rates
Economic Calendar
Watchlist
European Debt Crisis
Symbol Search
The Market Now




Personal Finance


Top Headlines
Saving & Investing
Real Estate
Retirement Planning
Financial Advisers
Taxes
Blog: Ventured & Gained
Real Cost Of
Money Gallery
Calculators
Watchlist (Portfolio Tracker)




Tech


Top Headlines
Social Media
Mobile & Wireless
Web
Enterprise Tech
TV, Games & Movies
Apple
Tech Deals
Global Tech
Slideshows
Videos




U.S. Politics


Sustainability


Top Headlines
Energy
Corporate Sustainability
Policy
Natural Resources
Health & Population
Slideshows
Videos
Blog: The Grid




Luxury


Top Headlines
Autos
Billionaires
Living
Property
Travel
Well Spent
Loot Blog
Pursuits Magazine
Videos




TV


Live TV
Channel Finder
Personalities
Apple TV
iPad App
Schedule
U.S.
Asia
Europe


Shows
Surveillance
Market Makers
Lunch Money
Street Smart
Bloomberg West
Game Changers




Video


Must See
Latest
Live TV
Shows
Playlist




Radio


Live Radio
Shows
Schedule
Personalities
Podcasts
Bloomberg Brief
Featured Podcasts and New Shows
Bloomberg View
Masters in Business
First Word
Surveillance
Bloomberg Advantage
In the Loop
Bloomberg Law
Taking Stock
Bloomberg Best
More Podcasts




Blogs


Global Tech
The Grid
Loot
The Market Now
Political Capital
Tech Deals
Ventured and Gained




Opinion




My Saved



Registration



Sign In



Bloomberg.com



Businessweek.com



Company



About
Blog
Careers
Diversity & Inclusion
News Mission
Philanthropy & Engagement
Press Room
Procurement
Sustainability




Products



Financial Products
Bloomberg Professional Service
Bloomberg Anywhere
Bloomberg Tradebook
Bloomberg Briefs
Bloomberg Indexes
Bloomberg SEF
Service Center
Customer Support
Enterprise Products
Enterprise Solutions
Trading Solutions
Industry Products
Bloomberg BNA
Bloomberg Government
Bloomberg Law
Bloomberg Link
Bloomberg New Energy Finance
Bloomberg Sports
Content Licensing




Bloomberg Anywhere



Mobile Apps



Bloomberg Visual Data


































Brett K. Haumann M.D., M.B.A.: Executive Profile & Biography - Bloomberg









































  





















































































July 28, 2017 9:36 PM ET
Pharmaceuticals

Company Overview of Theravance Biopharma, Inc.



SnapshotPeople 




OverviewBoard MembersCommittees



Executive Profile
Brett K. Haumann M.D., M.B.A.Senior VP of Clinical Development & Chief Medical Officer, Theravance Biopharma, Inc.AgeTotal Calculated CompensationThis person is connected to 0 Board Members in 0 different organizations across 3 different industries.47--
Background

		Dr. Brett K. Haumann, M.D., M.B.A. has been the Chief Medical Officer and Senior Vice President of Clinical Development at Theravance Biopharma, Inc. since March 1, 2016. Dr. Haumann served as Senior Vice President of Clinical Development and Operations at Theravance Biopharma, Inc. since December 2014. Dr. Haumann served as Vice President of Clinical Development at Theravance Inc. since October 2013. Dr. Haumann served as a Vice President Clinical Development and Operations ... at Theravance Biopharma, Inc. He served as Chief Medical Officer of Circassia Limited since September 2012 until July 3, 2013. Dr. Haumann has extensive experience of leading global phase III development programmes, managing interactions with regulatory agencies and scientific opinion leaders and co-ordinating market access and commercial activities. Dr. Haumann has over 15 years' experience of pharmaceutical development gained at Glaxo Wellcome and GlaxoSmithKline (GSK). He served as an Executive Director of Circassia Limited since September 2012 until July 3, 2013. During this time, he held a number of positions of increasing seniority and served as Vice President of Medicines Development Leader, where he led a multifunctional team developing GSK's next generation of inhaled respiratory products. Prior to his time in the pharmaceutical industry, Dr. Haumann practised internal medicine and conducted clinical research in South Africa. He gained his Medical Degree from the University of Witwatersrand, South Africa and also holds an MBA from the UK's Open University.Read Full Background




Corporate Headquarters
Ugland HouseGeorge Town, Grand Cayman 94080Cayman IslandsPhone: 650-808-6000Fax: --
Board Members Memberships
				There is no Board Members Memberships data available.
				Education
MBA Open University (UK)MD University of the Witwatersrand
Other Affiliations
Innoviva, Inc.Open University (UK)University of the WitwatersrandCircassia Pharmaceuticals Plc


Annual Compensation
				There is no Annual Compensation data available.
				Stocks Options
				There is no Stock Options data available.
				Total Compensation
				There is no Total Compensation data available.
			



Request Profile Update
















 












The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking 
	here.




Stock Quotes


Market data is delayed at least 15 minutes.







Company Lookup



COMPETITOR COMPENSATIONNamePosition/CompanyCompensationClive A. Meanwell M.D., Ph.D.Chief Executive Officer and DirectorThe Medicines Company$896.4KBrenton L. Saunders J.D.Chairman, Chief Executive Officer and PresidentAllergan plc$1.0MKenneth C. Frazier Chairman, Chief Executive Officer and PresidentMerck & Co., Inc.$1.5MCompensation as of Fiscal Year 2016.










Sponsored Financial Commentaries

Sponsored Links






Browse Companies
A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z
 | 
0
1
2
3
4
5
6
7
8
9






Request Profile Update

						Only a company representative may request an update for the company profile. Documentation will be required.
					  
To contact Theravance Biopharma, Inc., please visit .  Company data is provided by S&P Global Market Intelligence.  Please use this form to report any data issues.
					  


Information Missing - Please enter your information in the following field(s): 




Company Name

Your Name*

Your E-Mail Address*

Your Phone Number*

Type of Data*


Overview
Executives
Key developments
Similar companies
Transactions


Update Needed*

All data changes require verification from public sources.  Please include the correct value or values and a source where we can verify.


Cancel


Submit






Your requested update has been submitted
Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.


Close






























Publications Authored by Brett Haumann | PubFacts.com








































Brett Haumann
 Are you  Brett Haumann?   Register this Author




Register this Author






School of Translational MedicineUnited Kingdom 






Toggle navigation










Publications
















Publications
















10Publications


71Reads



 OF 






















The Study to Understand Mortality and Morbidity in COPD (SUMMIT) study protocol.
Authors:
Jørgen Vestbo,
Julie Anderson,
Robert D Brook,
Peter M A Calverley,
Bartolome R Celli,
Courtney Crim,
Brett Haumann,
Fernando J Martinez,
Julie Yates,
David E NewbyEur Respir J 2013 May 27;41(5):1017-22. Epub 2012 Sep 27.Dept of Respiratory Medicine J, Odense University Hospital and University of Southern Denmark, Odense, Denmark. May 2013




Download Full Paper











Once-daily fluticasone furoate is efficacious in patients with symptomatic asthma on low-dose inhaled corticosteroids.
Authors:
Eugene R Bleecker,
Eric D Bateman,
William W Busse,
Ashley Woodcock,
Lucy Frith,
Karen W House,
Loretta Jacques,
Angela M Davis,
Brett Haumann,
Jan LötvallAnn Allergy Asthma Immunol 2012 Nov;109(5):353-358.e4Center for Genomics and Personalized Medicine, Wake Forest University Health Sciences Winston-Salem, North Carolina, USA. November 2012




Download Full Paper











24-h duration of the novel LABA vilanterol trifenatate in asthma patients treated with inhaled corticosteroids.
Authors:
Jan Lötvall,
Eric D Bateman,
Eugene R Bleecker,
William W Busse,
Ashley Woodcock,
Richard Follows,
Jessica Lim,
Sally Stone,
Loretta Jacques,
Brett HaumannEur Respir J 2012 Sep 23;40(3):570-9. Epub 2012 Feb 23.Krefting Research Centre, University of Gothenburg, Box 424, SE 40530 Gothenburg, Sweden. September 2012




Download Full Paper











Efficacy and optimal dosing interval of the long-acting beta₂ agonist, vilanterol, in persistent asthma: a randomised trial.
Authors:
Richard Sterling,
Jessica Lim,
Lucy Frith,
Neil G Snowise,
Loretta Jacques,
Brett HaumannRespir Med 2012 Aug 19;106(8):1110-5. Epub 2012 Apr 19.Carolina Research, Respiratory Medicine, Orangeburg, SC 29118-2040, USA. August 2012




Download Full Paper











The efficacy and safety of the novel long-acting β2 agonist vilanterol in patients with COPD: a randomized placebo-controlled trial.
Authors:
Nicola A Hanania,
Gregory Feldman,
Wolfgang Zachgo,
Jae-Jeong Shim,
Courtney Crim,
Lisa Sanford,
Sally Lettis,
Frank Barnhart,
Brett HaumannChest 2012 Jul;142(1):119-127Respiratory and Medicines Development Centre, GlaxoSmithKline, Uxbridge, England.July 2012




Download Full Paper











Dose effect of once-daily fluticasone furoate in persistent asthma: a randomized trial.
Authors:
Eric D Bateman,
Eugene R Bleecker,
Jan Lötvall,
Ashley Woodcock,
Richard Forth,
Hilary Medley,
Angela M Davis,
Loretta Jacques,
Brett Haumann,
William W BusseRespir Med 2012 May 18;106(5):642-50. Epub 2012 Feb 18.Department of Medicine, University of Cape Town, Cape Town, South Africa. May 2012




Download Full Paper











Fluticasone furoate demonstrates efficacy in patients with asthma symptomatic on medium doses of inhaled corticosteroid therapy: an 8-week, randomised, placebo-controlled trial.
Authors:
William W Busse,
Eugene R Bleecker,
Eric D Bateman,
Jan Lötvall,
Richard Forth,
Angela M Davis,
Loretta Jacques,
Brett Haumann,
Ashley WoodcockThorax 2012 Jan 9;67(1):35-41. Epub 2011 Aug 9.Department of Medicine, University of Wisconsin, K4/910 CSC, 600 Highland Avenue, Madison, WI 53792, USA. January 2012




Download Full Paper











Fluticasone furoate: once-daily evening treatment versus twice-daily treatment in moderate asthma.
Authors:
Ashley Woodcock,
Eugene R Bleecker,
William W Busse,
Jan Lötvall,
Neil G Snowise,
Lucy Frith,
Loretta Jacques,
Brett Haumann,
Eric D BatemanRespir Res 2011 Dec 21;12:160. Epub 2011 Dec 21.School of Translational Medicine, University of Manchester, Manchester, UK. December 2011




Download Full Paper











Efficacy in asthma of once-daily treatment with fluticasone furoate: a randomized, placebo-controlled trial.
Authors:
Ashley Woodcock,
Eric D Bateman,
William W Busse,
Jan Lötvall,
Neil G Snowise,
Richard Forth,
Loretta Jacques,
Brett Haumann,
Eugene R BleeckerRespir Res 2011 Oct 6;12:132. Epub 2011 Oct 6.School of Translational Medicine, Manchester Academic Health Science Centre, University of Manchester, UK. October 2011




Download Full Paper











Evaluation of an ambulatory system for the quantification of cough frequency in patients with chronic obstructive pulmonary disease.
Authors:
Michael A Coyle,
Desmond B Keenan,
Linda S Henderson,
Michael L Watkins,
Brett K Haumann,
David W Mayleben,
Michael G WilsonCough 2005 Aug 4;1. Epub 2005 Aug 4.Physiology Program, Harvard School of Public Health, Boston, MA, USA. August 2005




Download Full Paper



 






















 OF 











﻿






























Very Positive News Coverage Extremely Likely to Affect Ann (NYSE:ANN) Stock Price - Chaffey Breeze













































 
















 



  
 
 
























Daily Ratings & News for Ann Inc

        
	Complete the form below to receive the latest headlines and analysts' recommendationsfor Ann Inc with our free daily email newsletter:










Follow @chaffeybreeze












Recent Posts

Bank of New York Mellon Corp Has $2.52 Million Stake in Party City Holdco Inc. (PRTY)
Xact Kapitalforvaltning AB Raises Position in CVS Health Corporation (CVS)
Meridian Investment Counsel Inc. Purchases 335 Shares of CVS Health Corporation (CVS)
Honeywell International Inc. (HON) Shares Sold by Zurcher Kantonalbank Zurich Cantonalbank
Swiss National Bank Acquires 552,100 Shares of Honeywell International Inc. (HON)
Swiss National Bank Has $591,000 Stake in Sangamo Therapeutics, Inc. (SGMO)
Resolute Forest Products Inc. (RFP) Position Held by Swiss National Bank
Marriot Vacations Worldwide Corporation (VAC) Stake Increased by UBS Asset Management Americas Inc.
Swiss National Bank Maintains Position in FutureFuel Corp. (FF)
American Woodmark Corporation (AMWD) Stake Cut by UBS Asset Management Americas Inc.
SolarEdge Technologies, Inc. (SEDG) Shares Bought by Swiss National Bank
Carpenter Technology Corporation (CRS) Stake Raised by UBS Asset Management Americas Inc.
TIAA CREF Investment Management LLC Has $3.71 Million Stake in U S Concrete, Inc. (NASDAQ:USCR)
Envestnet, Inc (NYSE:ENV) Shares Sold by TIAA CREF Investment Management LLC
Unifirst Corporation (UNF) Shares Sold by California Public Employees Retirement System
Regis Corporation (NYSE:RGS) Shares Bought by California Public Employees Retirement System
TIAA CREF Investment Management LLC Boosts Stake in Taylor Morrison Home Corp (TMHC)
TIAA CREF Investment Management LLC Sells 7,020 Shares of Mobile Mini, Inc. (MINI)
Piper Jaffray Companies Reiterates “Buy” Rating for Hologic, Inc. (HOLX)
Roche Holding Ltd. (VTX:ROG) Stock Rating Reaffirmed by J P Morgan Chase & Co







Very Positive News Coverage Extremely Likely to Affect Ann (NYSE:ANN) Stock Price


					Posted by Joanna Charbonneau on Jul 10th, 2017 // No Comments




Headlines about Ann (NYSE:ANN) have been trending very positive recently, Accern Sentiment Analysis reports. Accern ranks the sentiment of media coverage by monitoring more than 20 million blog and news sources in real time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Ann earned a news sentiment score of 0.52 on Accern’s scale. Accern also gave media coverage about the specialty retailer an impact score of 100 out of 100, indicating that recent media coverage is extremely likely to have an effect on the stock’s share price in the next several days. 
Here are some of the news headlines that may have impacted Accern’s rankings: 

Unsecured loans * Cash advance ann arbor * unsecured personal loans (channelbuzz.ca)
Short term loans ann arbor, michigan ~ personal loans for any credit ~ personal loans online (piolog.com)
Bouygues Energies & Services and Flybits, Inc. Announce a Strategic Partnership to Deliver the Connected Workplace of the Fut… (advfn.com)
Solar Alliance Announces Final Closing of Brokered and Non-Brokered Private Placement (feeds.benzinga.com)
Sirius Veterinary Orthopedic Center Announces Participation at Pick-a-Pooch Pet Adoption Event on July 16 and 17 (feeds.benzinga.com)

COPYRIGHT VIOLATION WARNING: “Very Positive News Coverage Extremely Likely to Affect Ann (NYSE:ANN) Stock Price” was originally  posted by Chaffey Breeze and is the property of of Chaffey Breeze. If you are reading this report on another site, it was illegally stolen and republished in violation of United States & international copyright and trademark legislation. The original version of this report can be viewed at https://www.chaffeybreeze.com/2017/07/10/ann-ann-given-media-sentiment-rating-of-0-52-updated-updated.html. 
Ann Company Profile
ANN INC., through its wholly owned subsidiaries, is a specialty retailer of women’s apparel, shoes and accessories sold primarily under the Ann Taylor and LOFT brands. The Company operates in four segments: Ann Taylor, LOFT, Ann Taylor Factory and LOFT Outlet. The Company operates approximately 1,030 retail stores in 47 states of the United States, the District of Columbia, Puerto Rico and Canada, comprising 245 Ann Taylor stores, 537 LOFT stores, 116 Ann Taylor Factory stores, 127 LOFT Outlet stores and five Lou & Grey stores.






Receive News & Ratings for Ann Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ann Inc and related companies with MarketBeat.com's FREE daily email newsletter.








 






















Latest News





Leave a Reply

Click here to cancel reply.




Name  (Required) 



Mail (will not be published)  (Required) 



Website












 

 
















































HAUMANN BRETT K Top Holdings  

































WhaleWisdom









Search All
Search 13F Filers Only
Search SEC Filer
Search Stocks Only
Search Mgmt Inv. Cos Only
ETFs Only
Search Active




















                      HAUMANN BRETT K
                    

•   SOUTH SAN FRANCISCO, CA
                      
How do I update this listing?




                                             Haumann Brett K is based out of South San Francisco.   
                                           














Summary
13D/G
Insider (Form 4)



   Create Email Alert
 




×
Email Notification.







                   ***Log In or
                   Sign-up
                   to see more advanced email alert options such as selecting any type of
                   SEC form, multiple filers or classes of filers, and much more.***
                 

                    ...or to simply have an email sent to you whenever we receive a new
                           13F filing from HAUMANN BRETT K, enter your
                    email address below and choose 'Submit'.
                

Your email:








Cancel














Contact Info




haumann brett k


901 GATEWAY BLVD

SOUTH SAN FRANCISCO
CA
                                                        
                                                    94080









Recent SEC Filings




4 filed on 05/23/2017
4 filed on 03/08/2017
4 filed on 02/22/2017
4 filed on 02/08/2017
4 filed on 11/22/2016
4 filed on 08/25/2016
4 filed on 08/23/2016
4 filed on 05/24/2016
4 filed on 03/17/2016
4 filed on 02/23/2016
















Schedule 13D and 13G events since 03/31/2017

Subscription required



 
Form 4 - Non-derivative Insider Transactions Since 03/31/2017
Loading...








Elevate your investments
Try it for free

















